The OPTIMISE‑AR paper was published in @thelancetoncol.bsky.social last week. This introduces a practical toolkit to support the analysis and visualisation of patient‑reported outcomes (PROs) in early‑phase dose‑finding oncology trials.
🧪

Including some bsky co-authors @biostatgirl.bsky.social @annaminchom.bsky.social @madelinepe.bsky.social @ethanbasch.bsky.social

Grateful to all co-authors and the many international experts, including patient advocates, across sectors and disciplines, who contributed to the Delphi survey and consensus process.
@mle-alger.bsky.social
@icr-ctsu.bsky.social

International Consensus-Driven Recommendations for Patient-Reported Outcome Research Objectives in Early Phase Dose-Finding Oncology Trials: OPTIMISE-ROR - PubMed This foundational guidance outlines key PRO research objectives in DFOTs. By facilitating the systematic integration of PROs, this guidance supports the utilization of patient-centered evidence for the tolerability and efficacy assessment of therapies to inform dose escalation, optimization, and reg …

Delighted to share OPTIMISE-ROR – recommendations to help embed patient-reported outcomes (PROs) more meaningfully in dose-finding oncology trials. It sets out core PRO objectives to support tolerability assessment, dose selection, and PRO strategy for subsequent studies. tinyurl.com/45thervu.

Professor Christina Yap, Academy Cross-Sector Experience Awardee, next to a quote that reads: "I’m thrilled to collaborate with AstraZeneca and Bayer through placements, advancing statistical methods to improve early-phase trials and patient-centred outcomes."

Congratulations to Cross-Sector Experience Award recipient @christinayap.bsky.social 🎉

Through this award Prof Yap will work with AstraZeneca & Bayer to improve the design of early-phase trials, ensuring they are more effective & impactful for patients.

👉 bit.ly/45a0VWy

#CrossSector @icr.ac.uk

A real pleasure running this workshop with you and Devin Peipert - thank you so much! Had such an engaging and interactive group too!

Thank you for the kind invitation to share insights on the value of PROs in phase I dose-finding trials. A fantastic conference in the beautiful city of Barcelona - I’ve learnt so much too! Such a privilege to be part of it!

Passionate about cancer trials, patient-reported outcomes (PROs) & innovative methods?

Join the Early Phase and Adaptive Trials Group at @icr-ctsu.bsky.social @icrlondon.bsky.social for an exciting undergraduate summer scholarship in early phase trials & PROs!

Deadline: 26/01/25
shorturl.at/1h565